Nuvectis Pharma Inc.

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Others were interested in
See all stocksFrequently asked questions
To buy Nuvectis Pharma Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Nuvectis Pharma Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Nuvectis Pharma Inc. is NVCT:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Nuvectis Pharma Inc. has its primary listing on NASDAQ (Small cap). You can trade Nuvectis Pharma Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Nuvectis Pharma Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Nuvectis Pharma Inc. as part of a broader investment portfolio.